EPISODE · Jul 10, 2019 · 31 MIN
#4 – How ECCMID 2019 went viral
from Breakpoints
Erin McCreary (@erinmccreary) and Ryan Shields (@ryankshields) review results of ASPECT-NP (Ceftolozane-tazobactam versus meropenem in patients with ventilated nosocomial pneumonia), CAMERA-2 (Combination therapy for methicillin-resistant Staphylococcus aureus bacteraemia), and Exebacase for patients with methicillin-resistant Staphylococcus aureus bacteraemia (Phase 2). Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/
Embed this episode
Ready to play
#4 – How ECCMID 2019 went viral
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.